The funding will support the development of a drug and digital approach to treat and manage major health conditions our society faces, starting with sleep disturbance and hypertension, with intentions to develop fully regulated, evidence-based drug and digital solutions for the NHS and international healthcare providers. The money was raised from Longwall Venture Partners, IQ Capital and Martlet, the investment arm of the Marshall of Cambridge group, with several leading Cambridge Angel investor...
READ MORE
|
The price regulator in the pharmaceutical industry, National Pharmaceutical Price Authority (NPPA) has discovered that the leading Pharma companies are overcharging customers for abundantly prevalent drugs in the market....
READ MORE
|
Bigtincan (ASX:BTH), the leader in mobile, AI-powered sales enablement automation, today announced the acquisition of AsdeqLabs, whose platform provides support for field-based employees and mobile service capabilities, helping to usher in the next evolution of service enablement and customer engagement for revenue accountability. With AsdeqLabs, Bigtincan strengthens its revenue enablement platform by expanding its content management and collaboration solutions to support customer engagem...
SOURCE
READ MORE
|
One brand-new FDA approval and one trial win for its blood cancer drug Gazyva added up to a double dose of good news for Roche Monday. The Swiss drugmaker snapped up a combo approval for lymphoma drug Polivy, then touted Gazyva trial results in a completely different field: lupus nephritis, a potentially fatal complication of the autoimmune disease systemic lupus erythematosus. In a phase 2 study, adding Gazyva to standard lupus nephritis treatment beat that standard of care alone alone at deliv...
READ MORE
|
Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions....
READ MORE
|
Homology Medicines Inc. (NASDAQ:FIXX) and UroGen Pharma Ltd. (NASDAQ:URGN) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation. Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is desi...
HOMOLOGY MEDICINES INC.
READ MORE
|